Influence of Azilsartan or Olmesartan on renin-angiotensin-aldosterone system.

Influence of Azilsartan or Olmesartan on renin-angiotensin-aldosterone system. - Influence of Azilsartan or Olmesartan on renin-angiotensin-aldosterone system.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011006

Enrollment

Registered

2013-06-19

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

essential hypertension

Interventions

Switch from Azilsartan to Olmesartan Switch from Olmesartan to Azilsartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who is taking Olmesartan for hypertension Patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: Patients from whom informed consent was not obtained

Design outcomes

Primary

Measure	Time frame
renin, angiotensin, aldosterone	—

Secondary

Measure	Time frame
UCG (LVMI, EF) BNP cystatin C, albuminuria, Ox-LDL Blood pressure, heart rate Cr, eGFR ABI, PWV side effect	—

Countries

Japan

Contacts

Public ContactHisakuni Sekino

Sekino Hospital clinical research ethics committee

asezai.med@gmail.com090539846038

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026